Delivery Order SPE2DB24D1007-SPE2DB25FBYXZ

Award Date 10/15/24
Potential Completion Date 10/16/24
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $9,914.10 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp (Corporate Office division) to procure 4,565,863,606 units of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. This delivery order contract is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 with DLA Troop Support Medical, which enables the agency to efficiently acquire a comprehensive range of medical commodities to...
The U.S. Defense Logistics Agency (DLA) awarded a $23,118.45 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corporation's Corporate Office division. The contract is for the supply of 4,565,964,631 units of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. This delivery order is part of a larger Indefinite Delivery Contract with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,563,485,132 units of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has a completion date of January 31, 2024 and a potential value of $3,734.62. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp by DLA, with a potential...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has a ceiling value of $24,788.61 and a period of performance through April 3, 2024. This delivery order is issued under a larger $999,999,999.00 indefinite delivery contract (IDC) between DLA and AmerisourceBergen Drug Corp to provide a...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed price delivery order contract worth $38,700.68 to AmerisourceBergen Drug Corporation's Corporate Office Division. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract has an ultimate completion date of August 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 and running through December 2025,...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the Amerisourcebergen Corporation, to provide 4,564,160,426 units of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has a ceiling value of $15,493.16 and a period of performance through April 4, 2024. This delivery order contract is a part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, which has...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $13,655.88 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 4,564,184,849 units of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. This order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp as the prime contractor. The IDC enables Amerisourcebergen to deliver a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $4,059.09 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of 4563942820 DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to AmerisourceBergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a delivery order contract valued at $10,260.96 to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a period of performance through May 29, 2024. This order was placed under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical, valued up to $999,999,999.00 through December...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of 4,564,205,110 units of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The delivery order, valued at $26,135.63, has an ultimate completion date of April 9, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA that serves as the primary contract vehicle for the company to...
  • SPE2DB24D1007
    Indefinite Delivery Contract
  • SPE2DB24D1007-SPE2DB25FBYXZ
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp for the supply of 4,566,108,780 units of the pharmaceutical product DUPIXENT 300 MG/2 ML PEN 2ML. The contract has a ceiling value of $19,356.90 and a period of performance through October 16, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has no set-aside designation.

Generated 1/14/25, 9:21 AM